Peter D Gorevic, MD
New York Magazine
Peter Gorevic is Professor of Medicine of Chief of the Division of Rheumatology. In ongoing studies, he is examining the pathogenesis of the various forms of amyloid disease, with emphasis on those that are concomitant with the aging process in man, including Alzheimer's disease, and articular amyloid often associated with osteoarthritis. Other studies focus on Dialysis Amyloidosis, a major cause of arthropathy and spondyloarthropathy in patients maintained by long-term dialysis. A variety of agents have been proposed to be generic therapeutics for the treatment of the amyloid diseases, including small peptides corresponding to the subsequences of amyloidogenic proteins, monoclonal antibodies, and compounds that interfere with binding to relevant confactors. A transgenic animal model for dialysis amyloidosis, and an in vitro model for cerebrovascular amyloid are under development, each of which will be used for the development of novel diagnostics and to test therapeutics. Other ongoing studies focus on the autoimmune phenomena and clinical deseases that are extrahepatic manifestations of hepatitis C Virus (HCU), and the potential use of this virus to provoke lymphoproliferative diseases such as non-Hodgkin's lymphoma. In particular, the localization of HCU to cryoprecipitable immune complexes is being examined, as well as the effect of biological such as interferon alpha in inhibitig viral replication and B cell proliferation. These studies are funded by NIH-NIDDK, NIH-NINDS, and the Alzheimer's Association.
- Long-term efficacy and safety of inotersen for hereditary transthyretin amyloidosis: NEURO-TTR open-label extension 3-year update
- The enigma of complement activation in mixed cryoglobulinemia
- Long-term safety and efficacy of patisiran for hereditary transthyretin-mediated amyloidosis with polyneuropathy: 12-month results of an open-label extension study
- Indirect treatment comparison of the efficacy of patisiran and inotersen for hereditary transthyretin-mediated amyloidosis with polyneuropathy
- Early data on long-term efficacy and safety of inotersen in patients with hereditary transthyretin amyloidosis: a 2-year update from the open-label extension of the NEURO-TTR trial
- Quality of life outcomes in APOLLO, the phase 3 trial of the RNAi therapeutic patisiran in patients with hereditary transthyretin-mediated amyloidosis
- Patisiran, an RNAi therapeutic for the treatment of hereditary transthyretin-mediated amyloidosis
- Inotersen treatment for patients with Hereditary transthyretin amyloidosis
- The complement system and C1q in chronic hepatitis C virus infection and mixed cryoglobulinemia
- Assessing mNIS+7<sub>Ionis</sub> and international neurologists' proficiency in a familial amyloidotic polyneuropathy trial
Patient Experience Rating
The Patient Experience Star Rating reflects our patients’ perception of how well their Mount Sinai physician communicated with them during an office visit. The Star Rating is based on patient responses to three questions on the Clinician & Group CAHPS (CG-CAHPS) Survey, a standardized questionnaire developed by Medicare. Responses are measured on a scale of 1 to 5, with 5 being the best score.
Explains in a way you understand
4.8 out of 5
4.9 out of 5
Likelihood to recommend
4.7 out of 5
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Below are financial relationships with industry reported by Dr. Gorevic during 2021 and/or 2022. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
- Best Doctors
- Gerson Lehrman Group
- Guidepoint Global, LLC.
Other activities: Examples include, but are not limited to, committee participation, data safety monitoring board (DSMB) membership
- UpToDate Inc./Wolters Kluwer Health
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.